Avastin, Lucentis, and Eylea are anti-VEGF injections used to treat conditions like wet AMD and diabetic macular oedema. They work in similar ways but differ slightly in licensing, dosing, and cost.
Similarities and differences
All three drugs block vascular endothelial growth factor to reduce leakage and swelling. Many patients achieve comparable visual outcomes.
- Lucentis and Eylea are specifically licensed for eye use
- Avastin is used off-label in ophthalmology but widely studied
- Eylea may allow slightly longer treatment intervals for some conditions
- Choice can depend on national guidelines, availability, and funding
Practical considerations
Your clinician will recommend a regimen based on your eye response. Switching between agents is sometimes helpful.
- Regular OCT scans track fluid and guide injection timing
- Side effects and risks, including infection, are similar and very low
- Cost differences may influence first-line choices in some health systems
- Discuss concerns about frequency, travel, and long-term treatment early on
